Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Itacitinib for GVHD and CRS Prophylaxis in Haplo-HCT
NCT03755414Phase 1Completed
- Sponsor
- Washington University School of Medicine
- Start
- Sep 2019
- Primary completion
- Apr 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of itacitinib in graft-versus-host disease (GVHD) and cytokine release syndrome (CRS) (2 arms), sponsored by Washington University School of Medicine. Primary endpoints: Number of Participants With Graft Failure at Day 35 and Number of Participants With Grades III-IV Acute GVHD at Day 100. Started Sep 2019; status: completed.
02
Drugs
itacitinib
03
Conditions
graft-versus-host disease (GVHD)cytokine release syndrome (CRS)
Beyond the preview
Go deeper on NCT03755414.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03755414.